Ribociclib Adds Over One Year of Survival in Advanced Breast Cancer

First-line combination therapy demonstrates a 24% relative reduction in risk of death compared to letrozole alone

Design MONALEESA-2 Phase 3 Trial Population Postmenopausal women with HR+, HER2- advanced breast cancer N 668 Duration Median follow-up: 80 months Comparator Placebo + Letrozole Year 2022

Key Performance Indicators

PRIMARY

Hazard Ratio (Death)

0.76

95% CI: 0.63–0.93

Significant Survival Benefit

PRIMARY

Median OS Gain

+12.5

Months

Clinically Meaningful

Statistical Significance

0.008

P Value

Below 0.05 threshold

6-Year Survival Rate

44.2%

vs 32.0% Placebo

Long-term durability

01

Median Overall Survival exceeds 5 years with Ribociclib

Patients in the Ribociclib arm lived a median of 12.5 months longer than those in the placebo arm.

02

Survival benefit widens over time (Kaplan-Meier Estimates)

The absolute difference in survival rates increases from 5.7% at 4 years to 12.2% at 6 years.

03

Survival benefit is consistent across key subgroups

Hazard ratios favor Ribociclib (<1.0) across age groups and metastatic sites, though confidence intervals widen for smaller subgroups.

04

Ribociclib delays the need for cytotoxic chemotherapy

Treatment extended the median time to first subsequent chemotherapy by nearly one year compared to placebo.

05

Neutropenia is the primary Grade 3/4 adverse event

While neutropenia rates are high with Ribociclib, other severe adverse events like hepatobiliary toxicity and QT prolongation remain relatively low.

06

Survival benefit persists despite high crossover in Placebo arm

34.4% of placebo patients received a CDK4/6 inhibitor as subsequent therapy, compared to only 21.7% in the Ribociclib arm, potentially diluting the observed OS benefit.

Editorial Conclusion

“Ribociclib plus letrozole establishes a new benchmark for first-line treatment in HR+/HER2- advanced breast cancer, offering a median overall survival exceeding 5 years.”

The 12.5-month survival advantage is statistically significant and clinically substantial.

Benefit is observed despite 34.4% of the placebo group receiving subsequent CDK4/6 inhibitors.

Treatment significantly delays the need for chemotherapy, preserving quality of life duration.

Clinical Implication

These results support the use of Ribociclib plus Letrozole as the standard of care for first-line therapy in this patient population.

Sources & Abbreviations

Abbreviations

Abbrev	Meaning
HR	Hazard Ratio
CI	Confidence Interval
OS	Overall Survival
AE	Adverse Event

Source

N Engl J Med 2022;386:942-50

DOI: 10.1056/NEJMoa2114663

Limitations

Underrepresentation of Black patients (2.5%)
Wide confidence intervals in smaller subgroups
High rate of crossover to CDK4/6 inhibitors in placebo arm required sensitivity analysis